Table 4.
Demographics and baseline characteristics: intent-to-treat population
| PARAMETER |
CLIN/RA GEL n=1008 |
CLINDAMYCIN GEL n=1002 |
|---|---|---|
| AGE (YEARS) | ||
| Mean Age ±SD | 19.1 ±7.5 | 19.0 ±7.0 |
| GENDER —n (%) | ||
| Male | 515 (51.1) | 455 (45.4) |
| Female–n (%) | 493 (48.9) | 547 (54.6) |
| RACE –n (%) | ||
| Caucasian | 765 (75.9) | 758 (75.6) |
| African American | 102 (10.1) | 97 (9.7) |
| Hispanic/Latino | 100 (9.9) | 103 (10.3) |
| American Indian/Alaskan | 1 (0.1) | 5 (0.5) |
| Asian/Pacific Islander | 25 (2.5) | 28 (2.8) |
| Other | 15 (1.5) | 11 (1.1) |
| FITZPATRICK SKIN TYPE —n (%) | ||
| Type I | 47 (4.7) | 47 (4.7) |
| Type II | 214 (21.2) | 214 (21.4) |
| Type III | 341 (33.8) | 339 (33.8) |
| Type IV | 231 (22.9) | 230 (23.0) |
| Type V | 106 (10.5) | 103 (10.3) |
| Type VI | 69 (6.8) | 69 (6.9) |
| BASELINE GLOBAL SEVERITY SCORE —n (%) | ||
| 3 (moderate) | 753 (74.7) | 747 (74.6) |
| 4 (severe) | 255 (25.3) | 255 (25.4) |
| BASELINE ABSOLUTE MEAN LESION COUNTS ± SD | ||
| Noninflammatory lesions | 49.0 ±20.7 | 48.9 ± 21.1 |
| Inflammatory lesions | 30.6 ±8.3 | 30.9 ±8.7 |
| Total lesions | 79.6 ± 24.1 | 79.8 ± 25.1 |